American Society of Hirudotherapy

Direct thrombin inhibitors

Review published in British Journal of Clinical Pharmacology (2011)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentLee CJ, Ansell JE · British journal of clinical pharmacology, 2011

Abstract

Heparins and vitamin K antagonists have been the primary agents used for anticoagulation in certain cardiovascular and thromboembolic diseases for over 50 years. However, they can be difficult to administer and are fraught with limitations. In response to the need for new anticoagulants, direct thrombin inhibitors (DTIs) have been developed and investigated for their utility in prophylaxis and treatment of venous thromboembolism (VTE), heparin-induced thrombocytopenia (HIT), acute coronary syndromes (ACS), secondary prevention of coronary events after ACS, and nonvalvular atrial fibrillation. Currently, four parenteral direct inhibitors of thrombin activity are FDA-approved in North America: lepirudin, desirudin, bivalirudin and argatroban. Of the new oral DTIs, dabigatran etexilate is the most studied and promising of these agents. This review discusses the clinical indications and efficacy of these direct thrombin inhibitors as well as future directions in anticoagulant therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsAntithrombinsArginineBenzimidazolesDabigatranHirudinsHumansPeptide FragmentsPipecolic AcidsPyridinesRecombinant ProteinsSulfonamidesThrombinVenous Thromboembolism

Summary

Review of direct thrombin inhibitors: four parenteral agents are FDA-approved in North America (lepirudin, desirudin, bivalirudin, argatroban), with oral dabigatran etexilate most studied, for VTE, HIT, acute coronary syndromes and nonvalvular atrial fibrillation.

Why This Matters for Hirudotherapy

This review surveys direct thrombin inhibitors (DTIs) developed to overcome the limitations of heparins and vitamin K antagonists, noting four parenteral agents FDA-approved in North America (lepirudin, desirudin, bivalirudin, argatroban) and dabigatran etexilate as the most studied oral DTI, across indications including VTE prophylaxis and treatment, heparin-induced thrombocytopenia, acute coronary syndromes, secondary prevention after ACS, and nonvalvular atrial fibrillation. It frames the pharmacological lineage rooted in leech hirudin: lepirudin and desirudin are recombinant hirudins and bivalirudin is a hirudin-derived analog, situating the medicinal leech at the historical root of an established anticoagulant drug class. Being a narrative review, it summarizes indications and efficacy reported in other studies rather than generating new comparative data, and it concerns these purified/synthetic drugs — not whole-leech hirudotherapy — reflecting the 2011 evidence and approval landscape.

Citation

Reference (Vancouver style)

Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581-592. doi:10.1111/j.1365-2125.2011.03916.x. PMID: 21241354

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 26, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.